Kimberly-Clark is acquiring Kenvue in a $48.7 billion cash-and-stock deal. I believe the deal is likely to close, and that Kenvue stock gives folks a decent way to buy Kimberly-Clark at a discount. There is still a solid deal spread here, and I think Kimberly-Clark is undervalued as well, offering additional upside once the deal closes.
A U.S. appeals court is expected to hear arguments on Monday from families seeking to revive their lawsuits over Tylenol, after the Trump administration publicly promoted their claims that the popular painkiller is linked to autism in children.
A Texas judge on Friday will consider state Attorney General Ken Paxton's bid to block Kenvue from paying a $398 million dividend to shareholders and from marketing Tylenol as safe for pregnant women.
| Household Products Industry | Consumer Staples Sector | Kirk L. Perry CEO | XMUN Exchange | US49177J1025 ISIN |
| US Country | 22,000 Employees | 12 Nov 2025 Last Dividend | - Last Split | 4 May 2023 IPO Date |
Kenvue Inc. is a global consumer health firm that offers a wide range of healthcare products through its diverse operational segments: Self Care, Skin Health and Beauty, and Essential Health. Founded in 2022 and headquartered in Skillman, New Jersey, Kenvue Inc. delivers a comprehensive portfolio of products designed to improve the wellness and health of consumers around the world. By leveraging well-known brands across its segments, Kenvue provides solutions for everyday health concerns, from pain relief and cold prevention to skincare and baby care.